Heart & lung : the journal of critical careSep 11, 2026

Links between activating glucagon-like peptide-1 receptors, inflammation, and heart failure from genetic studies

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 12, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce heart failure risk.

The exact mechanisms by which GLP-1RAs influence heart failure risk are not yet understood.
GLP-1RAs are associated with potential cardiovascular benefits.
Further research is needed to clarify the relationship between GLP-1RAs and heart failure.

Simplified

Full Text

Full text is available at the source.

View Full Text ↗

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

GLP-1 drugs don't build habits — and that gap is costing patients their results

5 days ago7 studies

Semaglutide slowed aging and extended lifespan in older female mice

1 week ago7 studies

GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes

2 weeks ago7 studies

Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes

3 weeks ago7 studies

A once-daily pill beat placebo on weight loss — and it wasn't semaglutide

4 weeks ago7 studies

GLP-1 drugs work even without weight loss — and scientists are finally mapping why

5 weeks ago7 studies

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

6 weeks ago7 studies

The brain region that explains why blocking and activating the same receptor both cause weight loss

7 weeks ago7 studies

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

8 weeks ago7 studies

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

9 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief